TLGY Acquisition registered with the SEC to offer 17.5 million units, each consisting of one Class A ordinary share and one-half of a warrant, as well as a contingent right to receive at least one-fourth of a warrant following an initial business combination.
The SPAC’s acquisition focus is on biopharma or technology enabled business-to-consumer (“B2C”) industries globally.
TGLY is led by Founder, Cahriman and CEO Jin-Goon Kim. Since 2018, he has served as an independent director of the board and on the nomination committee of DongDu International Group.
Mizuho is sole bookrunner. Baird is lead manager of the offering. The underwriters have the option to purchase up to an additional 2.625 million units to cover any over-allotments.
TLGY has applied to list on the Nasdaq under TLGY.U. Read more.
